Author + information
- Slobodan Dusan Obradovic,
- Boris Dzudovic,
- Nemanja Djenic,
- Radoslav Romanovic,
- Zoran Jovic and
- Marijan Spasic
Background: It is unknown whether ticagrelor treatment before and after primary percutaneous coronary intervention (pPCI) can reduce the inflammatory response and infarction size compared to clopidogrel.
Methods: Four hundred and sixty consecutive patients with ST-segment elevation myocardial infarction (STEMI) admitted to the single center for pPCI were pretreated with either 180 mg of ticagrelor (100 patients) or 600 mg of clopidogrel (360 patients). There was no significant difference according to baseline characteristics of two cohorts and there was no cross-over between antiplatelet drugs during hospitalization. Maximum blood levels of creatine-kinase MB (CK-MB – measured every 8 hours for 48 hours from admission), C-reactive protein (CRP), fibrinogen and brain natriuretic peptide (BNP) measured after 24 and 48 hours from admission, were compared between patients who received ticagrelor and clopidogrel.
Results: Patients who received ticagrelor had significantly lower blood level of maximum CK-MB [139 (70-275) IU/L vs. 207 (119-385) IU/L, p<0.001], CRP [11.96 (7.48-26.36) mg/L vs. 20.50 mg/L (10.20-52.00), p=0.004] and fibrinogen [3.90 (3.30-5.10) g/L vs. 4.45 (3.60-5.60) g/L, p=0.005]. Maximum level of BNP was not significantly different between two groups [146.94 (82.47-307.14) pg/ml vs. 185.00 (88.20-319.04) pg/ml, p=0.381].
Conclusions: Ticagrelor decreases inflammatory response and infarction size in STEMI patients treated with pPCI.
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Antiplatelet and Antithrombotic Agents in Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1296-311
- 2017 American College of Cardiology Foundation